Kerr Drug receives accreditation under ACHC’s Community Retail program
RALEIGH, N.C. — Kerr Drug has received approval for reaccreditation from the Accreditation Commission for Health Care, making it the first corporate organization to receive approval for ACHC’s new Community Retail program, the organization announced.
Launched in April, ACHC’s Community Retail program serves retail stores that sell prescription medications and commonly used durable medical equipment and supplies to the consumer. ACHC developed the program "in response to a need for an accreditation that was tailored specifically to the services and product offerings of a retail pharmacy," ACHC director of DMEPOS, Rx and sleep Tim Safley said.
"Kerr Drug is honored to work with a great organization in ACHC and is proud to be the first corporate organization to receive approval for community retail accreditation. We look forward to benefiting from continued relations with ACHC," Kerr Drug SVP store operations Mark Gregory said.
Teva launches authorized generic Actos
JERUSALEM — Teva Pharmaceutical Industries announced the launch of an authorized generic of a Type 2 diabetes drug.
The company launched pioglitazone hydrochloride tablets in the 15-mg, 30-mg and 45-mg strengths. The drug is a generic version of Takeda Pharmaceuticals’ Actos.
Annual sales of Actos in the United States were approximately $2.7 billion for the 12-month period ended in June, according to IMS sales data.
Ranbaxy launches authorized generic diabetes drug
PRINCETON, N.J. — Ranbaxy Labs has launched an authorized generic version of a diabetes drug made by Takeda Pharmaceutical, Ranbaxy said Friday.
Ranbaxy announced the launch, through subsidiary Ranbaxy Pharmaceuticals and under an agreement with Takeda, of pioglitazone hydrochloride tablets, an authorized generic version of Takeda’s Actos. An authorized generic is a branded drug marketed at a reduced price under its generic name, typically by a third-party company operating under contract with the original branded drug’s manufacturer.
Actos, used to treat Type 2 diabetes, had sales of $2.7 billion during the 12-month period ended in June, according to IMS Health.